



# FDA PMA Approval Webinar

**John McCutcheon, President & CEO**

**Pharoah Garma, Chief Regulatory Officer**

**Erik Strandberg, Chief Commercial Officer**

April 15, 2025

ASX:EBR

ersonal use only

# Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at [www.asx.com.au](http://www.asx.com.au).

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR’s notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. Such statements are typically identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘anticipates’, ‘intends’ and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR’s management. EBR’s results are reported under US GAAP. Certain financial data in this presentation is “non-IFRS financial information” under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR’s CHES Depositary Interests (“CDIs”) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

# Investment highlights

Developer of the world's first and only leadless pacemaker for heart failure

## High value market opportunity



### Unique solution

No competition as the WiSE CRT system is complementary to other leadless devices. It is the only leadless device to deliver CRT



### Large markets

Targeting an initial addressable market of US\$3.6bn




### Positive results

Safety and efficacy endpoints met for SOLVE-CRT trial and Breakthrough Device Designation granted



### FDA approved

PMA approval received on 11 Apr 2025, US PDT / 12 Apr 2025 AEST



### Clear commercial strategy in place



Progressing commercialisation activities to initial revenue in H2 2025 by targeting high-volume sites in the US

Well-capitalised through to initial commercialisation with cash and short-term investments of US\$66.0m / A\$106.1m<sup>(1)</sup>

# Cardiac Rhythm Management Market

Three key segments driving growth in the global cardiac rhythm management market


Worldwide CRM Market (~US\$13.6bn)<sup>(1)</sup>





# Traditional CRT systems are suboptimal

Traditional CRT systems use wires or leads to deliver energy to the heart, which can lead to many problems.



Leads can migrate and sometimes fracture



Leads can become a way for pathogens to reach the myocardium



Difficult to place



LV lead must be placed outside the heart to avoid blood clots



Coronary Sinus limits Left Ventricle (LV) lead placement locations



Leads can be associated with phrenic nerve stimulation

# EBR has a wireless solution for the heart

EBR's WiSE CRT System is the only wireless device that can deliver cardiac resynchronisation therapy

## WiSE CRT System fills the gap

The only leadless solution for left ventricle (LV) pacing

## Other wireless pacemakers are too big for LV pacing

Their size increases the risk of blood clots, restricting their use to right ventricle (RV) and right atrium (RA) pacing only

## Complementary solution

WiSE CRT System can be used in conjunction with wireless RV / RA pacemakers to deliver CRT

## Strong competitive protection

WiSE CRT System is protected by over 97 issued patents globally

### Left ventricle<sup>(1)</sup>



EBR Systems  
WiSE CRT System

### Right ventricle / atrium<sup>(1)</sup>



Medtronic  
Micra®



Boston  
Scientific  
Empower®



Abbott  
Aveir®


### Extravascular / Subcutaneous ICD



Boston  
Scientific  
Emblem®




Medtronic  
Aurora®



# FDA Approval of WiSE CRT System

EBR has successfully advanced the WiSE CRT System to FDA approval, having received an approval letter authorising commercial marketing



# Approved Indications Support US\$3.6bn TAM

The FDA has approved the WiSE CRT System with the expected indications

The WiSE CRT System is indicated for adult patients who are at least 22 years of age, are indicated for cardiac resynchronization therapy (CRT), have an existing implanted right ventricular pacing system, and are in one of the following two categories:

- Patients in whom previous coronary sinus lead implantation was unsuccessful, or where an implanted lead has been turned off – referred to as “previously untreatable”
- Patients with previously implanted pacemakers\* or ICD’s in whom standard CRT upgrade is not advisable due to known relative contraindications for CS lead or CRT device implantation, referred to as “high-risk upgrades”

\* Includes leadless pacemakers. Medtronic's Micra leadless pacemaker has been qualified for use with WiSE CRT. Abbott's Aveir leadless pacemaker has not yet been qualified for use with WiSE CRT, but testing conducted by EBR is in progress.

## Contraindications:

1. Patients on triple anticoagulant who cannot tolerate peri-procedural stopping of anticoagulation therapy
2. Patients who cannot tolerate, or are allergic or hypersensitive to, procedural anticoagulation or contrast agents, or to the post-procedural antiplatelet regimen



# Post-approval Study

EBR will undertake a post-approval study to help assure continued safety and effectiveness

## Post-approval study summary



Prospective, real-world, observational



320 subjects



Follow-up period of 5 years

## Primary end point and additional data



Primary endpoint: Rate of serious adverse events (SAEs) occurring within  $\leq 30$  days after the implantation related to the WiSE CRT System and/or the implantation procedure.




Additional data collected to include typical endpoints for CRT – success rates, HF symptoms, mortality, device performance, other physiological metrics and other complications

# Commercialisation pathway

Successful FDA approval follows positive pivotal trial results and strong track record with the FDA with focus now shifting to commercialisation activities

EBR is now focused on ramping up commercial activity, focused on:

- Optimising commercial capabilities
- Limited market release in H2 2025
- Direct, specialist sales force to execute plan




# Initial commercialisation strategy

EBR will leverage its established partnerships and presence in the US to drive initial sales growth



## Commercial Leadership

- EBR is expanding and optimizing its commercial capabilities in the US market to ensure the company is well positioned to drive growth and impact
- Commercial Leadership team in place:
  - Chief Commercial Officer
  - 2 x VPs of sales
  - VP Marketing & Market Access
  - Sr. Dir. Training & Education



## LMR Supports Adoption and Advocacy

- **2025:** Limited Market Release (LMR) targeting combination legacy sites and accounts where we can leverage existing Key Opinion Leader (KOL) relationships
- **2026+:** As the sales team expands, continue to penetrate strategically important, high-volume sites



## Direct, specialist sales force to execute plan

- Execution of commercial launch supported by specialised direct sales force to target high volume sites
- High calibre new hires supplemented by legacy WiSE CRT clinical & technical experts
- Growth driven by combination of increasing utilisation rates in existing sites and penetrating new accounts with sales force expansion

# US\$3.6bn initial addressable market


At commercial launch, EBR estimates an initial addressable market of ~US\$3.6bn<sup>(1)</sup>

## High Risk Upgrades - Leadless

- Patients with a leadless right ventricle pacemaker can only upgrade with WiSE CRT System to receive effective CRT
- WiSE CRT System paired with the Medtronic Micra (Abbott Aveir pending)\*

## High Risk Upgrades - Conventional

Patient requiring CRT, but is deemed too high risk for a conventional CS lead placement



## Acute Lead Failure

Unable to implant CRT wire in a new CRT patient.

## Chronic Lead Failure


Traditional CRT system implanted but has ceased to provide effective CRT

\*Medtronic's Micra leadless pacemaker has been qualified for use with WiSE CRT. Abbott's Aveir leadless pacemaker has not yet been qualified for use with WiSE CRT, but testing conducted by EBR is in progress.



# Reimbursement System

The reimbursement system in the US is a function of coding and coverage to determine the amount paid for a procedure



Coding

Coding allows uniformity in claims submission for a specific service – “The language of insurers”

- CPT
  - ICD-10-PCS
  - ICD-10-CM
  - HCPCS
  - APC
  - MS-DRG
- } Procedure and Diagnosis Codes
- } Payment Codes



Coverage

Will they pay for it?

Payor criteria for coverage whether implicit (no NCD) or explicit (with NCD) to ensure appropriate utilisation.



Payment

How much will they pay for it?

The amount paid for the procedure or bundle of services provided.

To offset the costs of new technologies CMS established NTAP and TPT.

# WiSE Reimbursement

EBR has multiple pathways for WiSE Reimbursement

## Medicare Coverage

### Transitional Coverage of Emerging Technologies (TCET)

- Active discussions with CMS. Timing TBD

#### Benefits of TCET:

- Early CMS engagement for an efficient review process
- Expedited Medicare coverage
- Transitional Medicare coverage for up to 5 years
- Expanded optionality for reimbursement programs available to EBR

## Medicare In-patient Payment

### New Technology Add-On Payment (NTAP)

- Effective 1 Oct 2025

#### Benefits of NTAP:

- Increased hospital adoption
- Reduced financial barriers for patients and improves access
- Validates the technology's innovation and clinical benefit
- Ensures near-term reimbursement support

## Medicare Out-patient Payment

### Transitional Pass-Through (TPT)

- Effective 1 Oct 2025

#### Benefits TPT:

- Increased hospital adoption
- Allows sales teams to present a clear reimbursement pathway to hospitals
- External validation that the technology represents a meaningful clinical advancement

# Favourable US market dynamics

Market dynamics in the US support initial adoption of the WiSE CRT System



## Market validation

- Support of Key Opinion Leaders (KOLs)
- Unmet need underscored by FDA Breakthrough Device designation
- CRT market is highly concentrated - targeting high-volume CRT procedure sites



## Low hospital adoption barriers

- Low barrier for opening new accounts
- No capital equipment required and reimbursement available post-approval
- Proven and refined implanter training program



## Reimbursement<sup>(1)</sup>

- Clear pathway to NTAP<sup>(1)</sup> and TPT<sup>(1)</sup> reimbursement schemes post FDA approval, which will provide payment to cover EBR's selling price
- WiSE one of first 5 technologies accepted onto CMS TCET<sup>(1)</sup> reimbursement pathway

# Summary

EBR remains driven to deliver superior treatment for patients suffering from cardiac rhythm diseases



Developer of the world's first and only leadless pacemaker for heart failure



EBR's WiSE® CRT System has no direct competitors and is complementary to other pacemaker technologies



FDA approval achieved in April 2025 authorising the US commercial marketing of EBR's WiSE CRT System



Clear commercial strategy in place focusing on high-volume procedure sites in the US, minimising execution risk



Significant market opportunity with an initial addressable market of US\$3.6bn and potential for further growth



Well-capitalised through to initial commercialisation with cash and short-term investments of US\$66.0m / A\$106.1m<sup>(1)</sup>



Thank you

# Expanding manufacturing capabilities

EBR has secured a new state-of-the-art facility at favourable terms to support long-term commercial growth and scale

## Significant Facility Expansion:

- New 11-year lease secured for 51,000 sq ft (4,751 sqm) facility
- Expansion of manufacturing capability from critical manufacturing processes to manufacture of complete units
- Expands EBR's manufacturing capacity to accommodate future growth and demand for WiSE

## Phased Financial Commitment:

- Rent payments deferred until January 2026
- Gradual space occupancy and rent scaling up annually to full occupancy by year four
- Landlord to finance approximately US\$4M in tenant improvements

## Timing

- Facility upgrades and qualifications to be completed progressively over the next year, with the full transition expected in H1 2026

